Common misconceptions

Common mistake
Wrong: Aplastic crisis is the leading cause of death in sickle cell disease.
Right: Acute chest syndrome is the leading cause of death in sickle cell disease; aplastic crisis is the most dangerous crisis in hereditary spherocytosis.
Aplastic crisis causes a dangerous transient drop in red cell production (parvovirus B19 stops erythropoiesis), but patients usually recover with supportive care. Acute chest syndrome — a syndrome of pulmonary vaso-occlusion with fever, hypoxia, and new infiltrates — is the leading cause of death in sickle cell disease because it can progress rapidly to respiratory failure despite intervention. The confusion probably comes from the word 'aplastic' sounding catastrophic; reserve that severity for hereditary spherocytosis, where aplastic crisis is the most feared complication.
Common mistake
Wrong: Hydroxyurea treats sickle cell disease by directly preventing HbS polymerization.
Right: Hydroxyurea increases fetal hemoglobin (HbF) production, which dilutes HbS and inhibits polymerization, reducing sickling episodes.
Hydroxyurea does not dock onto HbS or block polymerization directly — there's no direct molecular antagonism between the drug and the mutant hemoglobin. Instead, hydroxyurea is a ribonucleotide reductase inhibitor that, as a side effect, reactivates fetal hemoglobin (HbF, alpha2-gamma2) gene expression. HbF doesn't participate in HbS polymer formation, so higher HbF levels dilute HbS and physically interrupt the polymer lattice, reducing sickling frequency and severity. The clinical takeaway: hydroxyurea works upstream, at the level of gene regulation, not at the hemoglobin molecule itself.
Common mistake
Wrong: Staphylococcus aureus is the most common cause of osteomyelitis in sickle cell disease.
Right: Salmonella species are the most common cause of osteomyelitis in sickle cell disease due to functional asplenia and gut ischemia facilitating bacteremia.
S. aureus is the #1 cause of osteomyelitis in the general population, which is why students default to it — but sickle cell disease changes the risk profile completely. Autosplenectomy removes the filter that normally clears Salmonella bacteremia originating from gut ischemia (vaso-occlusion damages intestinal mucosa, allowing translocation). Salmonella species, not S. aureus, take advantage of this gap and seed ischemic bone. On Step 1, always ask whether the osteomyelitis case has a specific risk factor: sickle cell = Salmonella, neonates = S. aureus/GBS, IVDU = S. aureus or Pseudomonas.
Common mistake
Gap: Misses the mechanistic basis for why sickle cell trait confers protection against malaria
HbS heterozygotes (sickle cell trait) have a survival advantage against Plasmodium falciparum malaria because parasitized RBCs sickle and are cleared before the parasite can replicate, explaining the high HbS allele frequency in malaria-endemic regions.
In HbAS individuals, when Plasmodium falciparum infects an RBC, the cell is more likely to sickle under the relatively hypoxic conditions of the spleen. Sickled, parasitized cells are recognized and destroyed by splenic macrophages before the parasite can complete its lifecycle and replicate. This cuts the parasite burden dramatically, giving HbAS individuals a strong survival advantage in malaria-endemic regions — enough that natural selection has maintained the HbS allele at high frequency in sub-Saharan Africa, the Mediterranean, and the Middle East despite its lethality in the homozygous state.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the point mutation in HbS (Glu→Val at beta-globin position 6), how deoxygenation drives HbS polymerization and sickling, and why HbAS heterozygotes have a survival advantage against Plasmodium falciparum malaria in endemic regions.
  2. Distinguish the four major sickle cell crises — vaso-occlusive (most common), aplastic (parvovirus B19, sudden drop in Hgb), splenic sequestration (infants, spleen enlarges acutely), and acute chest syndrome (fever + pulmonary infiltrate + hypoxia) — and know that acute chest syndrome is the leading cause of death.
  3. Explain why functional asplenia from autosplenectomy puts sickle cell patients at high risk for encapsulated organisms (S. pneumoniae, H. influenzae, N. meningitidis) and specifically Salmonella osteomyelitis — not S. aureus.
  4. Know the rationale for penicillin prophylaxis (encapsulated organism prevention), vaccines (PCV, meningococcal), hydroxyurea (increases HbF production to dilute HbS), acute pain crisis management (IV fluids, O2, analgesics), exchange transfusion for acute chest, and bone marrow transplant as the only curative option.

Can you avoid these mistakes?

A 4-year-old with known HbSS presents with sudden painful enlargement of the spleen and hemoglobin drop from 9 to 4 g/dL. His mother says he was fine yesterday. What crisis is this, what age group is it most common in, and what is the acute management?
A 19-year-old with sickle cell disease develops fever, chest pain, hypoxia, and a new right lower lobe infiltrate on CXR. What is the diagnosis, and why is this the leading cause of death in sickle cell disease rather than aplastic crisis?
A 16-year-old with HbSS presents with pain and swelling over the right femur. X-ray shows periosteal elevation. What is the most likely causative organism, and what about sickle cell pathophysiology explains this organism preference?
You want to start a sickle cell patient on hydroxyurea. A classmate says it works by 'blocking HbS from polymerizing.' How would you correct them, and what lab value would you follow to confirm the drug is working as intended?

Related topics

See how your Anki deck covers this topic.

Upload your deck for a free audit →